1. Introduction
===============

Percutaneous coronary intervention (PCI) is one of the main coronary revascularization approaches in patients with stable coronary artery disease and acute coronary syndrome (ACS).^\[[@R1]\]^ In addition, with the progress of percutaneous transluminal coronary angioplasty (PTCA) and coronary stent implantation during the treatment of acute myocardial infarction (AMI), the clinical prognosis of those patients has been improved significantly. However, AMI remains one of the major diseases threatening human health and a leading cause of deaths worldwide.^\[[@R2]\]^

Among AMI patients, about 50% have single vessel disease (SVD), while about 40% to 60% have multivessel disease (MVD) and near 10% have MVD with chronic total occlusion (CTO) in noninfarct related artery (n-IRA).^\[[@R3],[@R4]\]^ Moreover, the morbidity and mortality of AMI in patients with MVD are twice of those in patients with SVD.^\[[@R5]\]^ The most severe manifestation of coronary artery disease is CTO. Up to 15% of the patients with ST-segment elevation myocardial infarction (STEMI) have CTO in the n-IRA.^\[[@R4]\]^ A growing body of evidence shows that high mortality of AMI is closely related to concurrent CTO in n-IRA among patients with MVD.^\[[@R6]--[@R9]\]^

A recent systematic review and meta-analysis demonstrated that CTO in n-IRA was an independent predictor of clinical outcomes in patients with AMI.^\[[@R10]\]^

A randomized controlled trial named EXPLORE evaluated the effect of CTO revascularization in n-IRA on left ventricle systolic function and clinical outcomes after PCI for STEMI.^\[[@R11]\]^ It was concluded that PCI of CTO within 1 week after the primary PCI was feasible and safe. Although the overall benefit of PCI of CTO in terms of left ventricular ejection fraction (LVEF) or left ventricular end diastolic volume (LVEDV) and major adverse cardiac events (MACE) rates was not found, several studies declared that successful revascularization of CTO in the n-IRA was associated with improved clinical outcomes in AMI patients undergoing PCI. The above results were inconsistent and the sample size in their studies was relatively small, which may skew the statistical analysis. In respect of this, we performed a meta-analysis examining the impact of revascularization of n-IRA with CTO on the mortality of AMI patients treated by the primary PCI.

2. Methods
==========

2.1. Ethical approval
---------------------

All analyses were based on previous published studies; thus, no ethical approval and patient consent are required.

2.2. Search strategy
--------------------

We conducted searches through Cochrane Controlled Trials Registry, PubMed, MEDLINE, and EMBASE databases for published articles using the following predefined search terms, "hronic total occlusion" OR "hronic occlusion" AND "yocardial infarction" OR "acute myocardial infarction" AND "PCI." Abstracts from selected major scientific meetings of cardiology (American Heart Association, American College of Cardiology, European Society of Cardiology, and Transcatheter Cardiovascular Therapeutics) were reviewed. References from reviews and selected articles were also screened for potential relevant citations. There were no language restrictions.

2.3. Eligibility criteria
-------------------------

Selection criteria for inclusion in the meta-analysis were as follows: AMI patients of STEMI treated by the primary PCI or non-ST elevation MI (NSTEMI) by the primary PCI; the diagnosis of CTO in n-IRA was made by coronary angiography; either a single-group cohort or a controlled comparison between patients who had successful PCI in n-IRA with CTO and those who had no or failed PCI; the time of PCI for CTO was 1 week or longer after PCI; available data on all-cause mortality and cardiac mortality or MACE; trials that reported outcomes of more than 3 months.

Definition of successful PCI was core lab-defined final TIMI flow grade ≥2, residual stenosis \<50%, and no loss of a major side branch.

Full-text articles and meeting abstracts were included.

Redundant reports and ongoing studies were excluded. Data extraction was performed independently by 2 reviewers. Discrepancies were resolved by reaching a consensus between the 2 reviewers.

2.4. Data extraction
--------------------

Two independent reviewers screened the data from the included studies using a predefined checklist for each study. Disagreements between reviewers were resolved by discussion until a consensus was reached. Data extraction and presentation for this article followed the recommendations of the PRISMA group. The primary efficacy end point was all-cause mortality. Secondary end points included cardiac mortality, MACEs, and nonfatal myocardial infarction. Stroke and repeat revascularization were also assessed. Outcomes were evaluated based on the longest follow-up period for each study. The Newcastle-Ottawa Scale (NOS) was employed as an assessment tool.

2.5. Data analysis
------------------

The meta-analysis was conducted in accordance with the general guidelines in the Cochrane Handbook for Systematic Reviews of Interventions, version 5.0.2. The Cochrane *Q* statistic and the *I*^2^ statistic were used to assess the heterogeneity across different trials. A Cochrane *Q* statistic with *P*-value ≤.1 was considered significant. The *I*^2^ statistic was used to measure the consistency among different trials, and 25%, 50%, and 75% indicated low, moderate, and high heterogeneity, respectively. A funnel plot was used to assess publication bias by plotting the standard error against the log risk ratio. Analyses were conducted using the RevMan software, version 5.3.

3. Results
==========

3.1. Studies characteristics
----------------------------

As is shown in Fig. [1](#F1){ref-type="fig"}, 55 articles were identified, of which 42 were excluded based on the abstract review. Thirteen full articles were assessed for eligibility. Of them, 8 studies were excluded because they investigated the impact of concurrent CTO in n-IRA on mortality.^\[[@R4],[@R12]--[@R17]\]^ Finally, 5 studies containing a total of 1083 patients were included in the analysis, of which there was 1 randomized controlled trial,^\[[@R11]\]^ and 4 observational studies.^\[[@R18]--[@R21]\]^ Details and baseline characteristics of the included studies are listed in Tables [1](#T1){ref-type="table"}--[5](#T5){ref-type="table"}. The quality of the enrolled studies was assessed using the Newcastle-Ottowa scale in Table [2](#T2){ref-type="table"}.
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The characteristics of single studies.
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The definitions of the outcome in each of the studies.
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3.2. Quantitative synthesis results
-----------------------------------

In the global analysis of all studies, successful PCI for n-IRA with CTO was associated with lower all-cause mortality during a median follow-up of 36 months (interquartile range, 19--42 months) compared with CTO (the absolute risk was 9.38% vs 19.50%; the odds ratio \[OR\] was 0.34, and the 95% confidence interval \[CI\] was 0.2--0.59; *P* = .0001) (Fig. [2](#F2){ref-type="fig"}).

![Forest plot of each result. And it illustrates successful PCI of n-IRA with CTO could significantly decrease all-cause mortality, cardiac mortality, major adverse cardiac events (MACE), and stroke in acute myocardial infarction patients.](medi-97-e9655-g006){#F2}
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Cochrane collaboration\'s tool for assessing risk of bias.
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Long-term cardiac mortality was reported in the above 5 studies.^\[[@R11],[@R18]--[@R21]\]^ Successful revascularization of CTO was closely linked with decreased long-term cardiac mortality (the absolute risk was 6.02% vs 12.55%; OR: 0.36, 95% CI: 0.19--0.68; *P* = .002).

MACEs were reported in 3 studies.^\[[@R20]--[@R22]\]^ There was a significant correlation between successful PCI of CTO and the lower incidence of MACEs (the absolute risk was 21.85% vs 43.48%; OR: 0.35, 95% CI: 0.24--0.5; *P* \< .00001).

The nonfatal myocardial infarction and repeat revascularization were evaluated in all included studies,^\[[@R11],[@R18]--[@R21]\]^ and there was no evidence suggesting that the successful PCI of CTO may affect their incidence. This conclusion was similar regarding to MI (the absolute risk was 3.19% vs 3.47%; OR: 0.78, 95% CI: 0.36--1.70; *P* = .54) and repeat revascularization (the absolute risk was 18.58% vs 17.18%; OR: 1.11, 95% CI: 0.43--2.87; *P* = .83).

Stroke was reported in only 4 studies,^\[[@R11],[@R19]--[@R21]\]^ and its incidence in the population who underwent successful PCI of CTO was significantly lower (the absolute risk was 1.26% vs 3.41%; OR: 0.36, 95% CI: 0.13--0.97; *P* = .04).

4. Discussion
=============

The present meta-analysis demonstrated an important association between the successful revascularization of n-IRA with CTO and the survival rate in AMI patients treated by PCI. In the global comparison of data collected from 1083 patients, it was observed that the successful PCI for n-IRA with CTO was related to lower all-cause mortality and cardiac mortality as well as lower incidence of MACE and stroke. In addition, it was proved that the successful PCI was not related to the increased risk of repeat revascularization and nonfatal myocardial infarction.

The EXPLORE trial reported heart function and MACE rates, and a significantly lower rate was not found, but a subgroup analysis suggested that PCI for n-IRA with CTO could still improve the outcomes of high-risk patients.^\[[@R11]\]^ However, it was shown that routine PCI of CTO did not result in higher LVEF and lower LVEDV at 4 months, and the reasons may be as follows: the complexity of the patients enrolled; lack of a specific protocol or technique for PCI of CTO; a lower successful rate of PCI of CTO; smaller sample size for evaluation of clinical endpoints. The presence of CTO led to a higher degree of complexity in the coronary artery diseases investigated in the study. In our study, 48.19% to 73.04% of patients had triple-vessel disease (TVD), and their percentage was higher compared to the EXPLORE trial, in which 43% of the patients had TVD.

According to the CREDO-Kyoto AMI registry, in AMI patients with MVD, the CTO in non-IRA was associated with an increased 5-year mortality.^\[[@R17]\]^

The PRAMI trial concluded that as compared with conservative treatments, preventive PCI of n-IRA was related to a lower risk of adverse cardiovascular events. In our study, CTO were all located at n-IRA and our data were consistent with those obtained from the previous study.^\[[@R22]\]^

Regrettably, the exact mechanisms of reduced mortality were not investigated, but some explanations might be inferred: First, patients with CTO might have a larger infarct size due to acute occlusion, thus CTO-PCI may save dying myocardium and prevent the infiltration area expansion.^\[[@R23]\]^ Second, the decrease in electrical instability increased the tolerance for future coronary occlusion events by reducing the risk of fatal arrhythmia. Third, patients with successful treatment with CTO-PCI may enhance their care about health, leading to lifestyle and other changes that may decrease the risk of stroke. A recent meta-analysis comparing complete and incomplete coronary revascularization has suggested that the former is associated with a 30% reduction of cardiac mortality in patients with MVD,^\[[@R24]\]^ whereas the main decisive factor for incomplete revascularization is known to be CTO.^\[[@R25],[@R26]\]^

Complete revascularization is beneficial for long-term survival of patients treated with multivessel PCI in an elective setting.^\[[@R25]\]^ Another meta-analysis of selective patients showed that the successful PCI for CTO was related to a 4.4% improvement in terms of absolute LVEF points.^\[[@R27]\]^ Successful CTO-PCI is a prerequisite for complete revascularization. The vast majority patients who underwent successful CTO-PCI had complete coronary revascularization, and it has been shown that complete revascularization in MVD patients was associated with longer survival. Furthermore, previous reports have demonstrated the clinical benefit of complete revascularization in patients with MVD and CTO.^\[[@R28],[@R29]\]^

At present, the time for PCI of n-IRA with CTO is not determined. Most experts agree that IRA PCI should be performed as soon as possible for AMI to save the dying myocardium, reduce the mortality rate in the acute phase; and elective intervention in the opening CTO to reduce long-term events. In the EXPLORE study,^\[[@R11]\]^ staged CTO-PCI attempt was performed up to 7 days from primary PCI. And it proved that this approach is feasible and safe. Although the preliminary results of the study were not satisfactory, it still posed challenges and reflections for our conventional intervention strategy.

Does the difference between the methods for revascularization affect the outcome? Ascione and other professors from the Royal Institute of Cardiology, Royal College of Bristol, UK, believe that coronary artery bypass grafting (CABG) should be performed on patients with chronic total occlusion of the coronary artery (CTO). Patients with CTO have a high probability of combining multiple ailments and also have high scores in the SYNTAX scoring system. Multiple risk factors make patients very variable in clinical and cardiac characteristics. CABG surgery is capable of performing both proximal and distal segments, consistent with the 2 trials by DECISION-CTO and EuroCTO. In addition, CABG long-term follow-up results are good, graft vascular patency rate higher. The use of left internal mammary artery instead of anterior descending artery is very efficient, long-term patency rate is also very impressive. Long-term patency of CTOs using saphenous vein is greater than 50%, with an average of 75% in recent years as technology advances.

But professor Weintraub believes that although most of the patients with chronic coronary artery occlusive disease (CTO) are currently treated with CABG, the current evidence is not enough to prove that CABG is a common treatment for CTO. Of these patients with CTO, 11% had PCI, 40% had CABG, and 49% had medication. In patients without CTO, 36% had PCI, 28% had CABG, and 35% had medication. In one study from Canada, 18.4% of patients with nonurgent diagnosis of coronary heart disease had CTO. Of these, 25% reported Q wave conduction in the CTO blood supply area, most of them had normal left ventricular function. Almost half of CTO in the right coronary artery. Although only 30% of patients use PCI, the success rate is as high as 70%.

Although more patients currently use CABG to treat CTOs, the rapid development of PCI technology will allow more CTO patients to be treated with PCI. PCI can be effective in relieving angina pectoris, but there are few studies on the treatment of angina pectoris by CABG. In terms of increased survival, data on PCI versus CABG are not enough, and some low-risk patients are likely to increase their risk if CABG is routinely performed in all CTO patients. In the current CABG treatment of CTO literatures, some literature is not a randomized controlled trial and have some preferences. So we believe that at present, there are several factors that should be considered to determine which CTO patients should be treated with CABG and to study the long-term prognostic outcome of CABG therapy and that more rigorous trials should be conducted to compare treatments to determine the optimal CTO treatment method.

Despite good outcomes after successful PCI, little is known about the outcomes after failed PCI. By reading the literature, it was found that patients with a failed CTO-PCI were much more likely to be referred for surgical revascularization, CABG. The possible reasons are as follows: First, mechanical trauma to a coronary artery resulted in frank perforation and required emergent cardiac surgery. Thus, the higher number of complications among the CTO failure group probably accounted for a higher number of emergent CABG in this group. Second, in some patients with MVD and unsuccessful CTO-PCI, even absent complications prompted a need for bypass surgery.^\[[@R30],[@R31]\]^

5. Conclusion
=============

This meta-analysis suggested that successful revascularization of n-IRA with CTO could improve long-term outcomes of AMI patients who underwent the primary PCI. However, it remains unclear which kind of AMI patients benefit most. The findings are significant for interventional cardiologists. It is implied that when exploring the choice of revascularization modalities for patients with CTO of n-IRA, preference might be given to revascularization of n-IRA with CTO in addition to considering lesion complexity, functional significance, patient characteristics, and syntax scores in accordance with the current international recommendations.^\[[@R32]\]^

6. Limitation
=============

Our study has some limitations. First, some retrospective studies were included and hence the results might be affected by unmeasured confounders and selection bias due to the retrospective, nonrandomized, and observational nature of the study design. Second, the lack of patient-level data prevented a comprehensive assessment to identify patient characteristics associated with the greatest clinical benefits, and subgroup analyses were not performed. Third, the number of patients in our study was small and STEMI and NSTEMI were not distinguished. Forth, the difference in body weight between the 2 groups was not analyzed and information about collateral circulation and viability/ischemia of the area supplied by the occluding artery was not provided.
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